Happify Health and Almirall have launched a digital solution to support patients with psoriasis

NEW YORK–(BUSINESS CHP) – Today, Good healthIntelligent Healing Company ™ and Almiral SA (BME: ALM), A global biopharmaceutical company focused on skin health has announced that Claro, a digital program developed through the two companies’ innovative partnership, is live and now available to people with psoriasis in Spain, Italy and the United Kingdom. Claro was created to improve the mental well-being of people with psoriasis through cognitive-behavioral therapy, positive psychology and attention.

Psoriasis is one of the most common skin diseases in the world, affecting about 60 million people worldwide2. A 2019 study in the Maedica, Journal of Clinical Medicine, found a clear link between skin psychology and the quality of life of people with psoriasis4. It is estimated that 20% to 30% of people worldwide with moderate to severe psoriasis also suffer from mental health problems such as anxiety and depression.1. Approximately 80% of those affected by psoriasis have mild to moderate symptoms, with direct health costs of treating psoriasis in excess of $ 65 billion a year.3.

“At Almirall, we are proud to offer psoriasis patients a wide range of medications that cover the full spectrum of the disease, from mild to severe. “Claro is helping us live up to our commitment to people living with psoriasis by providing them with an improved well-being solution for their well-being so they can get their lives back,” he said. Dr. Volker KoschelnyDr., Chief Medical Officer of Almirall.

“Psoriasis is a significant burden on the daily lives of 71% of people who suffer from it, according to the National Psoriasis Foundation in the United Kingdom.3“Said Theo Ahadome, senior vice president of commercialization at Happify Health. “We are very pleased with the level of commitment we have seen so far among Claro users, and this partnership allows us to explore the effectiveness of digital programs to engage psoriasis patients in the treatment of psoriasis and improve their quality of life. “

About Almiral

Almirall is a global biopharmaceutical company focused on skin health. We work with scientists and health professionals to meet patients’ needs through science to improve their lives. Our noble goal is at the heart of our work: “Transform patients’ worlds by helping them realize their hopes and dreams for a healthy life.” We invest in differentiated and innovative medical dermatology products to provide our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, ​​is publicly traded on the Spanish Stock Exchange and is a member of IBEX35 (ticker: ALM). Throughout its 78-year history, Almirall has maintained a strong focus on patient needs. Almirall currently has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with around 1,800 employees. Total revenues in 2021 are 836.5 million euros.

For more information, please visit www.almirall.com

About Happify Health

Happify Health is The Intelligent Healing Company ™. We reduce the gap between need and care by configuring customized digital therapeutic solutions and scale care solutions for today’s cloud healthcare. Our platform integrates AI with empathy, making treatment more personal, precise and connected to the whole care journey. We implement a full range of clinical care solutions – including digital therapy products, coaching, community and well-being – for pharmacy, health plans, businesses and individuals everywhere.

Our global platform is available in 10 languages, supports more than 10 chronic conditions and covers more than 20 million lives.

References

  1. HL Richards, DG Fortune, CE Griffiths, CJ Main. The contribution of stigma perceptions to disability in patients with psoriasis. J Psychosom Res., 50 (2001), pp. 11-15.

  2. Photo from the 2008 National Psoriasis Foundation Survey Offered by: PTT-24087-quality-of-life-problems-and-measurement-in-patients-with-psor (researchgate.net)

  3. EA Dowlatshahi, M. Wakkee, LR Arends, T. Nijsten. Prevalence and chances of depressive symptoms and clinical depression in patients with psoriasis: a systematic review and meta-analysis. J Invest Dermatol., 134 (2014), pp. 1542-1551.

  4. M. Esposito, R. Saraceno, A. Giunta, M. Maccarone, S. Chimenti. Italian study on psoriasis and depression. Dermatology., 212 (2006), pp. 123-127.

Leave a Comment

Your email address will not be published.